Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Mar 4, 2021 · 10-K · 63 days after period end · 0001564590-21-010715
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|
| Revenue | $4.23M | — | — |
| Net Income | -$17.72M | -$16.12M | -$8.86M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 4, 2021 · 63 d after period end
